UBS’s Aerie Pharmaceuticals AERI Stock Holding History

UBS’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-768	Closed	-$17K	–	10943
2014 Q1	$17K	Sell	768 -232	-23%	-$4.69K	﹤0.01%	8324
2013 Q4	$18K	Buy	+1,000	New	+$13K	﹤0.01%	8286

Other funds holding AERI

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

WSA

Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

UBS's AERI Position: Q2 2014 in Review

UBS sold out of Aerie Pharmaceuticals (AERI) in Q2 2014, closing a stake of 768 shares — an estimated $17K sold.

UBS first reported a position in AERI in Q4 2013 and held it in 2 quarters. The position peaked at $18K in Q4 2013. 60 funds tracked by Wall St. Rank hold AERI as of Q2 2014.

UBS reported no remaining Aerie Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
UBS sold 768 Aerie Pharmaceuticals shares in Q2 2014, an estimated $17K.
UBS first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 2 quarters.
UBS's Aerie Pharmaceuticals position peaked at $18K in Q4 2013.
60 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2014.

Based on UBS's 13F filing for Q2 2014, filed 14 Aug 2014.